Hyperbaric Oxygen Therapy for Wellness: What the Evidence Actually Shows

Hyperbaric oxygen therapy places a person inside a pressurised chamber — typically at 1.5 to 3.0 atmospheres absolute (ATA) — where they breathe 100% oxygen. At elevated pressure, oxygen dissolves into plasma and tissue fluid at concentrations far above what normal breathing achieves. This drives oxygen into hypoxic (oxygen-starved) tissue and is thought to reduce inflammation, promote new blood vessel growth, and accelerate wound healing.

The technology is not new: it has been used in clinical medicine for decades, primarily for conditions where oxygen starvation or dissolved gas bubbles are the core problem.

The clearest evidence for HBOT is in a defined set of acute and chronic medical conditions. The US FDA has cleared hyperbaric chambers for fourteen specific disorders, including carbon monoxide poisoning, decompression sickness, severe burns, non-healing diabetic foot ulcers, radiation injury, gas gangrene, sudden unexplained hearing loss, and certain severe infections. Insurance — including US Medicare — covers these applications.

The centrepiece of HBOT wellness marketing is a 2020 study from Tel Aviv University and Shamir Medical Center, led by Professor Shai Efrati. It investigated whether HBOT could reverse two cellular hallmarks of aging — shortening of telomeres (protective caps on chromosomes) and accumulation of senescent cells ('zombie cells' that no longer divide normally).

Healthy adults over 64 received sixty 90-minute HBOT sessions at 2 ATA over three months. In blood cells analysed, B-cell telomeres lengthened by up to 37.6% post-treatment. Senescent T helper cells declined by up to 37.3%.

These are striking numbers. But the study design has significant limitations that the wellness marketing rarely mentions.

In clinical research, a single uncontrolled trial is considered hypothesis-generating — it tells us something is worth investigating further, not that the treatment works. The critical missing ingredient in the Efrati 2020 study is a control group: people who went through the same protocol, same environment, same attention and expectation, but without the actual HBOT pressure and oxygen.

Without a control group, we cannot rule out that the telomere changes reflect something other than HBOT — perhaps the structured rest, social interaction, expectation effects, or simply normal biological variation over three months.

Telomere length in blood cells is also itself a contested biomarker: it correlates with biological aging in population studies, but whether increasing telomere length in blood cells via an intervention actually extends healthy lifespan or reduces disease risk has not been demonstrated in humans.

As of 2026, no randomised controlled trial has tested HBOT specifically for longevity outcomes in healthy adults.

Wellness clinics and spas frequently market HBOT for conditions including anti-aging, athletic recovery, skin rejuvenation, immune enhancement, cognitive enhancement, autism, cancer, and long COVID. Cleveland Clinic explicitly states that 'there currently isn't enough research and testing to conclude that hyperbaric oxygen therapy safely and effectively treats' these conditions. Harvard Health similarly distinguishes the FDA-approved applications from unproven wellness claims.

A particularly important nuance: the wellness industry often uses 'mild hyperbaric' chambers at 1.3 ATA with ambient air or lower oxygen concentrations — substantially different from the 2.0 ATA medical chambers used in clinical research. The Efrati 2020 study used 2.0 ATA with 100% oxygen. Whether mild-chamber protocols produce any of the observed cellular effects is not established.

HBOT is not without risk. A systematic review and meta-analysis of 24 randomised controlled trials (n=1,497) found adverse effects in 30.1% of HBOT recipients versus 10.4% of controls — a statistically significant difference. The most common adverse effects are ear discomfort and middle ear barotrauma (3.38× increased risk versus controls), and ocular effects including temporary myopia (2.37× increased risk).

At higher pressures (≥2.0 ATA), adverse effects increase sharply: relative risk 7.99 compared to controls. At pressures below 2.0 ATA, adverse effects were comparable to controls.

Oxygen toxicity seizures are the most serious acute risk, historically cited as roughly 1 in 10,000 treatments, though more recent data suggest closer to 1 in 2,000–3,000 sessions — not a negligible risk, particularly for someone pursuing many sessions. These seizures typically stop when normal air breathing resumes. Temporary hyperoxic myopia is nearly universal in patients receiving extended treatment courses but resolves within six to eight weeks after cessation.

Fire and explosion risk is inherent in oxygen-enriched, pressurised environments; this is why accreditation and trained staff matter. The FDA recommends treatment only in accredited, medically-supervised facilities.